|Bid||0.00 x 800|
|Ask||42.50 x 1000|
|Day's Range||42.08 - 42.51|
|52 Week Range||34.32 - 46.47|
|Beta (3Y Monthly)||0.52|
|PE Ratio (TTM)||22.77|
|Earnings Date||Apr 29, 2019 - May 3, 2019|
|Forward Dividend & Yield||1.44 (3.43%)|
|1y Target Est||44.46|
A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday. Nearly 90 percent of patients who received the combination therapy were still alive after 12 months compared with about 78 percent of patients who were alive after a year when treated with the older drug Sutent, data showed. Merck on Monday released interim data from the trial, saying the combination reduced the risk of death by 47 percent compared with Sutent.
Announcement: Moody's announces completion of a periodic review of ratings of Pfizer Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Pfizer Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Bristol-Myers Squibb could still be in play, an analyst said Friday, suggesting Johnson and Johnson, Pfizer or Amgen could make a bid. That would break up Bristol's takeover of Celgene.
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Growth drivers On its fourth-quarter earnings conference call, GlaxoSmithKline (GSK) highlighted the prioritization of R&D (research and development)
FDA accepts Sarepta's (SRPT) regulatory application seeking approval for DMD therapy, golodirsen, and grants priority review. A decision is expected in August 2019.
Pfizer Inc NYSE:PFEView full report here! Summary * Perception of the company's creditworthiness is neutral * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for PFE with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding PFE totaled $14.08 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NeutralThe current level displays a neutral indicator. PFE credit default swap spreads are within the middle of their range for the last three years.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Bayer is banking on the mild side effects of its experimental prostate cancer drug darolutamide, as it prepares to take on established rival products by Pfizer and Johnson & Johnson. The drug, tested on early stage prostate cancer that does not respond to hormonal therapy, was shown to be safe to use with only fatigue as the most serious side effect, Bayer said on Thursday, citing a phase-three study that could be decisive for regulatory approval. Given the cancer is not yet spreading and patients are still relatively unburdened by the disease, a drug's tolerability is a key concern for the generally elderly men taking it, said Robert LaCaze, Bayer's head of oncology.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 13) Abbott Laboratories (NYSE: ABT ) Ionis Pharmaceuticals ...
Pfizer holds a lead in the erectile dysfunction market even as generics erode sales of its once-blockbuster male libido treatment, Viagra. According to GoodRx, 65 percent of ED prescriptions filled from Dec. 1, 2018, to Jan. 31, 2019, were for Viagra or its generic version. Pfizer has been able to maintain a significant share in the erectile dysfunction market thanks in part to launching its own generic version of the blue, diamond-shaped pill.
Conatus (CNAT) completes enrollment in a phase IIb study on emricasan, being developed for the treatment of patients with fibrosis or cirrhosis caused by NASH.
How Pfizer and Eli Lilly Stack Up in February(Continued from Prior Part)Expense guidance for fiscal 2019 In its fourth-quarter earnings investor presentation, Pfizer (PFE) guided for adjusted cost of sales as a percentage of revenues of 20.8% to
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets priority review in the United States. The decision is expected in June.
How Pfizer and Eli Lilly Stack Up in February(Continued from Prior Part)Growth drivers In its fourth-quarter earnings conference call, Pfizer (PFE) highlighted innovative health drugs such as Ibrance, Xtandi, Eliquis, and Xeljanz, its vaccines
How Pfizer and Eli Lilly Stack Up in February(Continued from Prior Part)Dividend projections Pfizer (PFE) and Eli Lilly (LLY) reported dividends per share of $1.36 and $2.25 in fiscal 2018, respectively. Analysts expect Pfizer’s dividend per share
The "Dogs of the Dow" is one of the simplest, most well-known dividend strategies on Wall Street. And investors who choose to jump in during 2019 will be shooting for their fifth straight year of market-beating returns, observes Brett Owens, editor of Contrarian Outlook.
Bristol-Myers' (BMY) oncology drug, Sprycel in combination with chemotherapy gets EC approval to treat pediatric patients with newly diagnosed Ph+ ALL.
How Pfizer and Eli Lilly Stack Up in February(Continued from Prior Part)EPS guidance for fiscal 2019In its fourth-quarter earnings conference call, Pfizer (PFE) has guided for non-GAAP diluted EPS of $2.82–$2.92 for fiscal 2019 excluding the
How Pfizer and Eli Lilly Stack Up in February(Continued from Prior Part)Revenue guidance for fiscal 2019 In its fourth-quarter earnings conference call, Pfizer (PFE) has guided for revenues of $52 billion to $54 billion for fiscal 2019 driven by the
How Pfizer and Eli Lilly Stack Up in FebruaryStock price movements On February 8, Pfizer (PFE) closed at $42.23, 1.27% higher than its previous closing price, 27.20% higher than its 52-week low of $33.20, and 9.12% below its 52-week high of $46.47.
Drugmaker Merck & Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemotherapy drug Sutent. Merck said the treatments when used as the initial treatment for advanced renal cell carcinoma (RCC) reduced the risk of death by about 47 percent in its late-stage trial. Keytruda has been Merck's most important growth driver with its domination of the lucrative lung cancer space, and shows no sign of slowing as it produces positive clinical data and adds approvals for different types of cancer.
Not intended for UK-based media ROCKLAND, Massachusetts and NEW YORK , Feb. 11, 2019 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada , ...
Data to be presented at the 2019 Genitourinary Cancers Symposium NEW YORK and TOKYO , Feb. 11, 2019 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji ...